Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK’s FluLaval Approval Raises Estimated Influenza Vaccine Doses To 115 Mil.

This article was originally published in The Pink Sheet Daily

Executive Summary

FluLaval is approved by FDA for immunization of adults against influenza Oct. 5.

You may also be interested in...



GSK Vaccine Manufacturing Plan Alternates Pandemic And Seasonal Flu

Results from one of two Phase I pandemic flu vaccine trials in the third quarter will support accelerated European regulatory efforts.

GSK’s Second Flu Vaccine Would Boost Capacity To 30 Mil. Doses

GSK submits a BLA for FluLaval, acquired as part of its 2005 purchase of ID Biomedical, to FDA March 23.

GSK To Gain Fluviral Vaccine Through Acquisition Of ID Biomedical

GlaxoSmithKline plans to acquire ID Biomedical for $1.4 bil., a deal that could provide GSK with a second flu vaccine in the U.S. for the 2006/2007 flu season.

Topics

UsernamePublicRestriction

Register

MT142313

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel